Basic Information
| Drug ID | DDPD04835 |
|
| Drug Name | Maraviroc | |
| Molecular Weight | 513.6655 | |
| Molecular Formula | C29H41F2N5O | |
| CAS Number | 376348-65-1 | |
| SMILES | CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1 | |
| External Links | ||
| DRUGBANK | DB04835 | |
| PubChem Compound | 3002977 | |
| PDR | 607 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
Not Available
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Reference |
|---|---|---|---|---|---|---|
| Bioavailability | 23.0 | % | 23 | % | PO, oral; | DRUGBANK | Bioavailability | 33.0 | % | 33 | % | PO, oral; | DRUGBANK |
| Clearance | 0.56 | L/h/kg | 9.4 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 194.0 | L | 194.0 | L | DRUGBANK | Volume of Distribution | 2.3 | L/kg | 2.3 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 16.0 | h | 14-18 | h | DRUGBANK | Half-life | 12.8 | h | 12.8 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Protein Binding | 76.0 | % | ~76 | % | plasma proteins; human, homo sapiens; | DRUGBANK |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for children | 600.0 | mg/day | 600 | mg/day | PO, oral | Selzentry | maraviroc | PDR |
| Max dose for children | 300.0 | mg/day | 300 | mg/day | PO, oral | Selzentry | maraviroc | PDR |
| Max dose for children | 600.0 | mg/day | 600 | mg/day | PO, oral | Selzentry | maraviroc | PDR |
| Max dose for children | 200.0 | mg/day | 200 | mg/day | PO, oral | Selzentry | maraviroc | PDR |
| Max dose for children | 150.0 | mg/day | 150 | mg/day | PO, oral | Selzentry | maraviroc | PDR |
| Max dose for children | 160.0 | mg/day | 160 | mg/day | PO, oral | Selzentry | maraviroc | PDR |
| Max dose for children | 100.0 | mg/day | 100 | mg/day | PO, oral | Selzentry | maraviroc | PDR |
| Max dose for adolescents | 600.0 | mg/day | 600 | mg/day | PO, oral | Selzentry | maraviroc | PDR |
| Max dose for adolescents | 300.0 | mg/day | 300 | mg/day | PO, oral | Selzentry | maraviroc | PDR |
| Max dose for adolescents | 600.0 | mg/day | 600 | mg/day | PO, oral | Selzentry | maraviroc | PDR |
| Max dose for adolescents | 200.0 | mg/day | 200 | mg/day | PO, oral | Selzentry | maraviroc | PDR |
| Max dose for adults | 600.0 | mg/day | 600 | mg/day | PO, oral | Selzentry | maraviroc | PDR |
| Max dose for adults | 1200.0 | mg/day | 1200 | mg/day | PO, oral | Selzentry | maraviroc | PDR |
| Max dose for adults | 300.0 | mg/day | 300 | mg/day | PO, oral | Selzentry | maraviroc | PDR |
| Max dose for geriatric | 600.0 | mg/day | 600 | mg/day | PO, oral | Selzentry | maraviroc | PDR |
| Max dose for geriatric | 1200.0 | mg/day | 1200 | mg/day | PO, oral | Selzentry | maraviroc | PDR |
| Max dose for geriatric | 300.0 | mg/day | 300 | mg/day | PO, oral | Selzentry | maraviroc | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1